ABBV

AbbVie Inc. · NYSE · Healthcare · USD · 10-K for 2025, filed 2026-02-20

Figures on this page computed 2026-11-08 12:24 UTC

Last close

288.24USD

Market data, 2026-11-05

Except where said otherwise: 10-K for 2025, filed 2026-02-20

122.9xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-20
The filing itself
16.1%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-02-20
- 10-K for 2025, filed 2026-02-20
- 10-K for 2025, filed 2026-02-20
- 10-Q for 2025, filed 2026-11-03
- 10-K for 2025, filed 2026-02-20
- 10-Q for 2025, filed 2026-11-03
The filing itself
6.9%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-02-20
- 10-K for 2025, filed 2026-02-20
The filing itself
29.1%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-02-20
- 10-K for 2025, filed 2026-02-20
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-02-20
- 10-Q for 2025, filed 2026-11-03
The filing itself
2.4%Dividend yield
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
- computed
- computed
- computed
- computed
- Computed from the filing for 2025, filed 2026-02-20

Price is the furthest below its sector's middle: 0.10 against 0.33 on the market's range.

Five bars, one line

lens 7 of 9

1.35x

0.64x

1.10x

1.13x

2.16x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-05

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-20

Sales1.35x
Its own average over 10 years, 45.17B.
Profit0.64x
Its own average over 10 years, 6.62B.
Free cash flow1.10x
Its own average over 10 years, 16.23B.
Debt1.13x
Its own average over 10 years, 60.74B.
Price2.16x
Its own average over 11 years, 133. Market data, 2026-11-05

Price is furthest from its own average, at 2.16 times.

Sales is 1.35 times its own 10-year average; Profit is 0.64 times its own 10-year average; Free cash flow is 1.10 times its own 10-year average; Debt is 1.13 times its own 10-year average; Price is 2.16 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-20

Sales against its own 10-year average1.35
Source
filed
Statement
income
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
The filing itself
Profit against its own 10-year average0.64
Source
filed
Statement
income
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
The filing itself
Free cash flow against its own 10-year average1.10
Source
filed
Statement
income
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
The filing itself
Debt against its own 10-year average1.13
Source
filed
Statement
income
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
The filing itself
Price against its own 11-year average2.16Market data, 2026-11-05
Source
market
Taken on
2026-11-05
Reported in
USD